Anne Runyan, BA , and colleagues point out that, despite increasing cancer costs in the United States, payers’ willingness and ability to manage oncology drugs remains limited.
Anne Runyan, BA , and colleagues point out that, despite increasing cancer costs in the United States, payers’ willingness and ability to manage oncology drugs remains limited.
Anne Runyan, BA , and colleagues...